We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience, read our Cookie Policy

Cerenis Initiates Phase 2 Study of CER-001, in Patients with Acute Coronary Syndrome

News   Mar 21, 2011

 
Cerenis Initiates Phase 2 Study of CER-001, in Patients with Acute Coronary Syndrome
 
 
 

RELATED ARTICLES

Study Finds Commercially Available Antibodies Are Not Binding Their Target

News

In a new study, researchers have tested the binding specificity of commercial antibodies to the C9ORF72 protein, and explored a novel validation approach.

READ MORE

Will a Next-generation Therapy for Diabetes Soon Be Available?

News

In order to improve diabetes therapy, researchers at the University of Geneva (UNIGE), Switzerland, have identified a protein called S100A9 which, under certain conditions, seems to act as a blood sugar and lipid regulator while avoiding the most harmful side effects of insulin.

READ MORE

How Do Empty Spaces Make a Protein Unstable?

News

Partial unfolding of proteins may affect their stability and is a challenge in the industry. So how does a cavity destabilize a protein? Would such a cavity be empty? These are questions that researchers from Aarhus University answer in a new study.

READ MORE

 

Like what you just read? You can find similar content on the communities below.

Proteomics & Metabolomics

To personalize the content you see on Technology Networks homepage, Log In or Subscribe for Free

LOGIN SUBSCRIBE FOR FREE